Company’s 36-month beta value is 1.70.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TNXP is 7.35M, and currently, short sellers hold a 15.37% ratio of that floaft. The average trading volume of TNXP on July 03, 2025 was 937.46K shares.
TNXP) stock’s latest price update
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP)’s stock price has decreased by -5.71% compared to its previous closing price of $37.3. However, the company has seen a 3.47% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-02 that Combination treatment of mTNX-1700 (mTFF2-MSA fusion protein) with anti-PD1 antibody was associated with increased survival and decreased metastases in animal models of gastric cancer relative to anti-PD1 treatment alone mTNX-1700 treatment was associated with activation of cancer-killing CD8+ T Cells and limiting neutrophil-mediated immune evasion TNX-1700 (hTFF2-HSA fusion protein) is in preclinical development for gastric and colorectal cancers CHATHAM, N.J., July 02, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the publication of a paper entitled, “A CXCR4 Partial Agonist, Improves Immunotherapy by Targeting Immunosuppressive Neutrophils and Cancer-Driven Granulopoiesis,”1 in the peer-reviewed journal Cancer Cell, that represents a collaboration between scientists at Tonix and Columbia University’s Medical School and presents data demonstrating that treatment with murine TNX-1700 (mTNX-1700) increased survival and decreased metastases in animal models of gastric cancer.
TNXP’s Market Performance
Tonix Pharmaceuticals Holding Corp (TNXP) has experienced a 3.47% rise in stock performance for the past week, with a -7.59% drop in the past month, and a 101.55% rise in the past quarter. The volatility ratio for the week is 7.90%, and the volatility levels for the past 30 days are at 9.31% for TNXP. The simple moving average for the last 20 days is -2.18% for TNXP stock, with a simple moving average of 59.29% for the last 200 days.
Analysts’ Opinion of TNXP
ROTH Capital, on the other hand, stated in their research note that they expect to see TNXP reach a price target of $4. The rating they have provided for TNXP stocks is “Buy” according to the report published on April 18th, 2019.
ROTH Capital gave a rating of “Buy” to TNXP, setting the target price at $6 in the report published on August 18th of the previous year.
TNXP Trading at 20.48% from the 50-Day Moving Average
After a stumble in the market that brought TNXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.95% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNXP starting from LEDERMAN SETH, who purchase 4,000 shares at the price of $21.55 back on May 15 ’25. After this action, LEDERMAN SETH now owns 4,005 shares of Tonix Pharmaceuticals Holding Corp, valued at $86,200 using the latest closing price.
Stock Fundamentals for TNXP
Current profitability levels for the company are sitting at:
- -7.22 for the present operating margin
- 0.3 for the gross margin
The net margin for Tonix Pharmaceuticals Holding Corp stands at -11.46. The total capital return value is set at -0.4. Equity return is now at value -91.44, with -80.39 for asset returns.
Based on Tonix Pharmaceuticals Holding Corp (TNXP), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -105.64.
Currently, EBITDA for the company is -74.94 million with net debt to EBITDA at 1.86. When we switch over and look at the enterprise to sales, we see a ratio of 12.71. The receivables turnover for the company is 3.03for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.31.
Conclusion
In a nutshell, Tonix Pharmaceuticals Holding Corp (TNXP) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
